Trials / Completed
CompletedNCT04367051
Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction
Withdrawal of Spironolactone Treatment for Heart Failure With Improved Left Ventricular Ejection Fractraction: an Open-label Randomized Controlled Pilot Study (With-HF Trial)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study is a randomized controlled pilot trial to evaluate whether withdrawal of spironolactone is safe and associated with re-deterioration of left ventricular function in patients with heart failure with improved ejection fraction. The aim of current trial is to test the hypothesis that withdrawal of spironolactone would not be associated with relapse of significant clinical deterioration of left ventricular systolic function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Withdrawal of Spironolactone | Other recommended medications for heart failure than spironolactone will be continued for withdrawal group. |
| DRUG | Continuation of spironolactone | Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily. |
Timeline
- Start date
- 2020-08-13
- Primary completion
- 2021-12-10
- Completion
- 2022-06-30
- First posted
- 2020-04-29
- Last updated
- 2023-10-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04367051. Inclusion in this directory is not an endorsement.